Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Announces Third Quarter 2004 Financial Results
Oct 25, 2004
|
81.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today reported financial results for the third quarter and nine months ended September 30, 2004.
"We made significant progress in advancing the clinical development of our lead drug candidate, edifoligide (E2F Decoy) for the treatment...
|
|
|
Corgentech to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
Oct 19, 2004
|
66.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that Richard P. Powers, the company's vice president and chief financial officer, will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on Tuesday, October 26, 2004 at 10:...
|
|
|
Corgentech to Announce Third Quarter 2004 Results and Host Conference Call on October 25, 2004
Oct 18, 2004
|
69.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 18, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will announce financial results for the third quarter 2004 after the markets close on Monday October 25, 2004 and will hold a teleconference at 4:30 p.m. Eastern time that day. John McLaughlin, Corgentech's pres...
|
|
|
Corgentech Licenses Novel Peptide Delivery System From Cyclacel to Assist Systemic Delivery of TF Decoys
Sep 27, 2004
|
74.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif. and DUNDEE, Scotland, Sep 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, and Cyclacel Group plc, a United Kingdom-based biopharmaceutical company, announced today that Corgentech has entered into an exclusive license to utilize Cyclacel's Penetratin(R) Endonuclea...
|
|
|
Corgentech Plans to Expand Clinical Product Pipeline With Phase 1/2 Trial of NF-KB Decoy in Eczema
Sep 22, 2004
|
76.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sep 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that it plans to initiate a Phase 1/2 clinical trial in the first half of 2005 in eczema with NF-Kappa-B Decoy (NF-KB Decoy), a highly selective and potent inhibitor of immune and inflammatory res...
|
|
|
Click here to download our most recent fact sheet.